Nanoparticles made of poly(butyl cyanoacrylate) (PBCA) or poly(lactic-co-glycolic acid) (PLGA) coated with polysorbate 80 or poloxamer 188 enable the transport of cytostatics such as doxorubicin across the blood-brain barrier (BBB). Following intravenous injection to rats bearing intracranially the very aggressive glioblastoma 101/8 these particles loaded with doxorubicin significantly increased the survival times and led to a complete tumor remission in 20–40% of the animals. Moreover, these particles considerably reduced the dose-limiting cardiotoxicity and also the testicular toxicity of this drug. The drug transport across the BBB by nanoparticles appears to be due to a receptor-mediated interaction with the brain capillary endothelial cells, which is facilitated by certain plasma apolipoproteins adsorbed by nanoparticles in the blood.
KornblithP.L., WalkerM.: Chemotherapy for malignant gliomas.J Neurosurg, 68: 1–17, 1988.
3.
ReardonD.A., WenP.Y.: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.The Oncologist, 11: 152–164, 2006.
4.
HuncharekM., MuscatJ, GeschwindJ.F.: Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis.Anticancer Res, 18: 4693–4697, 1998.
5.
BrandesA.A., PasettoL.M., MonfardiniS.: New drugs in recurrent high grade gliomas.Anticancer Res, 20: 1913–1920, 2000.
6.
RobinsonP.J.: Osmotic opening of the blood-brain barrier and brain tumor chemotherapy. In: Methods in Neurosciences, pp 35–50, 1994.
7.
RoullinV-G, DeverreJ-R, LemaireL., HindréF., Venier-JulienneM-C, VienetR., BenoitJ-P: Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres.Eur J Pharm Biopharm, 53: 293–299, 2002.
8.
KreuterJ.: Nanoparticulate systems for brain delivery of drugs.Adv Drug Deliv Rev, 47: 65–81, 2001.
9.
KreuterJ.: Transport of drugs across the blood-brain barrier by nanoparticles.Curr Med Chem – Centr Nerv Syst Agents, 2: 241–249, 2002.
10.
KreuterJ.: Nanoparticles as drug delivery systems for the brain. In: Microencapsulation, Methods and Industrial Applications,BenitaS. (Ed), 2nd ed, pp 689–706, Taylor and Francis, New York, USA, 2006.
11.
KreuterJ.: Nanoparticulate carriers for drug delivery to the brain. In: Nanoparticles as Drug Carriers, TorchilinV.P. (Ed), pp 527–547, Imperial College Press, London, 2006.
12.
GelperinaS.: Brain delivery by nanoparticles. In: Nanoparticle Technology for Drug Delivery, GuptaR.B., KompellaU.B., pp 273–318, Taylor and Francis, New York, USA, 2006.
13.
KreuterJ.: Nanoparticles. In: Encyclopedia of Pharmaceutical Technology, Vol 10,SwarbrickJ., BoylanJ.C. (Eds), pp 165–190, M Dekker, New York, 1994.
14.
GulyaevA.E., GelperinaS.E., SkidanI.N., AntropovA.S., KivmanGYa, KreuterJ.: Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.Pharm Res, 16; 1564–1569, 1999.
15.
SteinigerS.C.J., KreuterJ., KhalanskyA.S., SkidanI.N., BobruskinA.I., SmirnovaZ.S., SeverinS.E., UhlR., KockM., GeigerK.D., GelperinaS.E.: Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles.Int J Cancer, 109: 759–767, 2004.
16.
AmbruosiA., GelperinaS., KhalanskyA.S., TanskiS., TheisenA., KreuterJ.: Influence of surfactants, polymer, and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.J Microencapsul, 23: 582–592, 2006.
17.
PetriB., BootzA., KhalanskyA., HekmataraT., MüllerR., UhlR., KreuterJ., GelperinaS.: Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants.J Controlled Rel, 117: 51–58, 2007.
18.
AlyautdinR.N., PetrovV.E., LangerK., BertholdA., KharkevichD.A., KreuterJ.: Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.Pharm Res, 14: 325–328, 1997.
19.
MichaelisK., HoffmannM.M., DreisS., HerbertE., AlyautdinR.N., MichaelisM., KreuterJ., LangerK.: Covalent linkage of apolipoprotein E to albumin-nanoparticles strongly enhances drug transport into the brain.J Pharmacol Exp Ther, 317: 1246–1253, 2006.
20.
KreuterJ., HekmataraT., DreisS., VogelT., GelperinaS., LangerK.: Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.J Controlled Rel, 118: 54–58, 2007.
21.
AlyautdinR.N., TezikovE.B., RamgeP., KharkevichD.A., BegleyD.J., KreuterJ.: Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study.J Microencapsul, 15: 67–74, 1998.
22.
KreuterJ., AlyautdinR.N., KharkevichD.A., IvanovA.A.: Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles).Brain Res, 674: 171–174, 1995.
23.
KreuterJ., RamgeP., PetrovV., HammS., GelperinaS.E., EngelhardtB., AlyautdinR., von BriesenH., BegleyD.J.: Direct evidence that polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drugs to nanoparticles.Pharm Res, 20: 409–416, 2003.
24.
SchroederU., SommerfeldP., UlrichS., SabelB.A.: Nanoparticle technology for delivery of drugs across the blood-brain barrier.J Pharm Sci, 87: 1305–1307, 1998.
25.
FrieseA., SeillerE., QuackG., LorenzB., KreuterJ.: Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release system.Eur J Pharm Biopharm, 49: 103–109, 2000.
26.
StanA.C., CasaresS., RaduD., WalterG.F., BrumeanuT.D.: Doxorubicin-induced cell death in highly invasive human gliomas.Anticancer Res, 19: 941–950, 1999.
27.
Sanchez de JuanB., von BriesenH., GelperinaS.E., KreuterJ.: Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays.J Drug Target, 14: 614–622, 2006.
28.
CouvreurP., GrislainL., LenaertsV., BrasseurF., GuiotP., BiernackiA.: Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. In: Polymeric Nanoparticles and Microspheres,GuiotP., CouvreurP. (Eds), pp 27–93, CRC Press, Boca Raton, USA, 1986.
29.
KattanJ., DrozJ.P., CouvreurP., MarinoJ-P, Boutan-LarozeA., RougierP., BraultP., VranckxH., GrognetJ-M, MorgeX., Sancho-GarnierH.: Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles.Invest New Drugs, 10: 191–199, 1992.
RamgeP., UngerR.E., OltroggeJ.B., ZenkerD., BegleyD., KreuterJ., von BriesenH.: Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)–nanoparticles by human and bovine primary brain capillary endothelial cells.Europ J Neurosci12, 1931–1940, 2000.
32.
AlyautdinR.N., ReichelA., LöbenbergR., RamgeP., KreuterJ., BegleyD.J.: Interaction of poly-(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.J Drug Target, 9: 209–221, 2001.
AmbruosiA., KhalanskyA.S., YamamotoH., GelperinaS.E., BegleyD.J., KreuterJ.: Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly-(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.J Drug Target14, 97–105, 2006.
35.
AmbruosiA., YamamotoH., KreuterJ.: Body distribution of polysorbate-80 and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v. administration in rats.J Drug Target13, 535–542, 2005.
MaedaH.: The enhanced permeability and retention (EPR) effect in tumour vasculature: the key role of tumour-selective macromolecular drug targeting.Adv Enzyme Regul, 41: 189–207, 2001.
38.
BriggerI., MorizetJ., LaudaniL., AubertG., AppelM., VelascoV., Terrier-LacombeM-J, DesmaeleD., d'AngeloJ., CouvreurP., VassalG.: Negative preclinical results with stealth® nanosphere-encapsulated doxorubicin in an orthotropic murine brain tumor model.J Controlled Rel, 100: 29–40, 2004.
39.
GelperinaS.E., KhalanskyA.S., SkidanI.N., SmirnovaZ.S., BobruskinA.I., SeverinS.E., TurowskiB., ZanellaF.E., KreuterJ.: Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.Toxicol Letters, 126: 131–141, 2002.
40.
PereverzevaE., TreschalinI., BodyaginD., MaksimenkoO., LangerK., DreisS., AsmussenB., KreuterJ., GelperinaS.: Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity.Int J Pharm, 337: 346–356, 2007.
41.
PereverzevaE., TreschalinI., BodyaginD., MaksimenkoO., KreuterJ., GelperinaS.: Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats.Toxicol Letters, (in press).
LückM.: Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. PhD Thesis, Freie Universität Berlin, pp 14–24, 137–154, 1997.
